Novel peptide therapy targeting obesity, diabetes, and aging
Johns Hopkins University researchers have developed novel AMPK-targeting peptides that address metabolic disorders like obesity and diabetes. By promoting mitochondrial fission and restoring mitochondrial health, these peptides help regulate blood glucose, reduce fat accumulation, and improve metabolic function. The technology is available for licensing and corporate partnerships.
Overview
Researchers at The Johns Hopkins University have developed novel AMPK-targeting peptides designed to treat metabolic disorders, including obesity, diabetes, and age-related conditions. These therapeutic candidates address mitochondrial dysfunction—a common underlying factor in metabolic disease—by promoting mitochondrial fission. By restoring healthy mitochondrial dynamics and activity, these peptides help improve high blood glucose levels and reduce excessive glucose production in the liver. Furthermore, preliminary research suggests these peptides possess potential antitumor activity.
Technical specifications
- Mechanism of Action: The peptides activate AMPK (the master regulator of cellular metabolism) by blocking negative phosphorylation at serine 496. This activation initiates mitochondrial fission, which breaks down dysfunctional mitochondria (megamitochondria) and stimulates the removal of damaged ones.
- Metabolic Benefits: In animal models and human hepatocyte studies, the peptides have been shown to inhibit excessive liver glucose production, improve high blood glucose, decrease fat levels, and enhance mitochondrial metabolism.
- Additional Capabilities: The peptides have demonstrated potential for antitumor activity via p53-mediated apoptosis.
- Current Scope: The research platform encompasses multiple designed peptides, including those identified as Pa496h and Pa496m.
Technology readiness level
The technology is currently in the development stage. Research has been validated through in vitro assays, cellular assays, animal testing, and testing on human tissue samples. The university is actively seeking commercial partners for licensing and further development. Based on this, it is assessed at TRL 4.
About Johns Hopkins University
Johns Hopkins University is a comprehensive private research university headquartered in Baltimore with a large research enterprise and a culture of discovery and translation. Integrated with a major academic health system, the university offers access to clinicians, patient populations, biorepositories, and audited trial operations. A research park near the medical campus, plus startup incubators and corporate engagement teams, enable co-location, pilots, and fast iteration. A major university‑affiliated research center expands applied R&D and prototyping capacity, and proximity to Washington, DC links partners to federal agencies and regulators. Research is supported by federal funding from NIH, NSF, DoD, and others, and a dedicated technology transfer office manages IP, licensing, and startup formation.
delivered to your inbox.